However, it must be noted that while the diagnosis of MS per se did not appear to be widely recognized clinically, its components were recognized and clinically managed as indicated, most patients were placed on statins following their AMI regardless of lipid profile; new medication for diabetes was started in 5 patients (5%); ACE-inhibitors and/or beta blockers were prescribed in the majority of patients prior to discharge. This evidence concerns the gene ACE and diabetes mellitus.